Therapeutic Response

EGFR activating variants status confers therapeutic sensitivity to Dacomitinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Vizimpro (dacomitinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.